Plasma phosphatidylcholine alterations in cystic fibrosis patients: Impaired metabolism and correlation with lung function and inflammation

Cellular Physiology and Biochemistry

Volumn 35, Issue 4, 2015, Pages 1437-1453

  Grothe, Judith ^a   Riethmüller, Joachim ^a,b   Tschürtz, Sandra M ^a   Raith, Marco ^a   Pynn, Chris J ^a,c   Stoll, Dieter ^a,c   Bernhard, Wolfgang ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Departments of General Pediatrics HematologyandOncology   (Germany)

^c ALBSTADT SIGMARINGEN UNIVERSITY   (Germany)

Author keywords

Choline deficiency; Cystic Fibrosis; Phospholipid metabolism; Stable isotope labeling in patients

Indexed keywords

BETAINE; BIOLOGICAL MARKER; CHOLINE; DEUTERIUM; INTERLEUKIN 6; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE METHYLTRANSFERASE; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; ELECTROSPRAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; IN VIVO STUDY; INFLAMMATION; ISOTOPE LABELING; LUNG FUNCTION; MALE; METABOLIC DISORDER; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; BLOOD; CHEMISTRY; KINETICS; LIVER; LUNG; METABOLISM; PATHOLOGY; PHYSIOLOGY; YOUNG ADULT;

ADULT; ARACHIDONIC ACID; BETAINE; CHOLINE; CYSTIC FIBROSIS; DEUTERIUM; DOCOSAHEXAENOIC ACIDS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFLAMMATION; INTERLEUKIN-6; ISOTOPE LABELING; KINETICS; LIVER; LUNG; MALE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINE N-METHYLTRANSFERASE; YOUNG ADULT;

EID: 84925426320     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373964     Document Type: Article

References (51)

1. Bradbury NA: Intracellular CFTR: Localization and function. Physiol Rev 2011;79:S175-S191.
2. Cystic Fibrosis Foundation Patient Registry: Annual Data Report. Bethesda, Maryland, 2010, 32 p.; http://www.cff.org/UploadedFiles/LivingWithCF/CareCenterNetwork/PatientRegistry/2010-Patient-Registry-Report.pdf.
3. Canadian Cystic Fibrosis Foundation Registry: Annual Report, Toronto, Ontario, 2011, 35 p.; http://www. cysticfibrosis.ca/wp-content/uploads/2013/10/Registry2011FINALOnlineEN.pdf.
4. Colombo C, Battezzati PM, Crosignani A, Morabito A, Costantini D, Padoan R, Giunta A: Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology 2002;36:1374-1382.
5. Williams SM, Goodman R, Thomson R, Mchugh K, Lindsell DRM: Ultrasound evaluation of liver disease in cystic fibrosis as part of an annual assessment clinic: a 9-year review. Clin Radiol 2002;57:365-370.
6. Herrmann U, Dockter G, Lammert F: Cystic fibrosis-associated liver disease. Best Pract Res Clin Gastroenterol 2010;24:585-592.
7. Freudenberg F, Broderick AL, Yu BB, Leonard MR, Glickman JN, Carey MC: Pathophysiological basis of liver disease in cystic fibrosis employing a DeltaF508 mouse model. Am J Physiol Gastrointest Liver Physiol 2008;294:G1411-G1420.
8. Lindblad A, Glaumann H, Strandvik B: Natural history of liver disease in cystic fibrosis. Hepatology 1999;30:1151-1158.
9. Zeisel SH: Dietary choline: biochemistry, physiology, and pharmacology. Ann Rev Nutr 1981;1:95-121.
10. Walkey CJ1, Yu L, Agellon LB, Vance DE: Biochemical and evolutionary significance of phospholipid methylation. J Biol Chem 1998;273:27043-27046.
11. Li Z, Agellon LB, Vance DE: Phosphatidylcholine homeostasis and liver failure. J Biol Chem 2005;280:37798-37802.
12. Quinton PM: Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis. Lancet 2008;372:415-417.
13. Chen AH, Innis SM, Davidson AG, James SJ: Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. Am J Clin Nutr 2005;81:686-691.
14. Scheele GA, Fukuoka SI, Kern HF, Freedman SD: Pancreatic dysfunction in cystic fibrosis occurs as a result of impairments in luminal pH, apical trafficking of zymogen granule membranes, and solubilization of secretory enzymes. Pancreas 1996;12:1-9.
15. Nouri-Sorkhabi MH, Chapman BE, Kuchel PW, Gruca MA, Gaskin KJ: Parallel secretion of pancreatic phospholipase A2, phospholipase A1, lipase and colipase in children with exocrine pancreatic dysfunction. Pediatr Res 2000;48:735-740.
16. Koc H, Mar MH, Ranasinghe A, Swenberg JA, Zeisel SH: Quantitation of choline and its metabolites in tissues and foods by liquid chromatography/electrospray ionization-isotope dilution mass spectrometry. Anal Chem 2002;74:4734-4740.
17. Greenberger NJ, Isselbacher KJ: Diseases of the gallbladder and bile ducts; in: Fauci A, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB (eds): Harrison's principles of internal medicine. New York, McGraw-Hill, 1998, pp 1725-1726.
18. DRI DIETARY REFERENCE INTAKES FOR Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. A Report of the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Reference Levels of Nutrients, Food and Nutrition Board, Institute of Medicine, National Academy Press, Washington, D.C., 1998; http://www.nap.edu/catalog/6015.html.
19. The AOCS Lipid Library: Plasma lipoproteins-composition, structure and biochemistry, 2013; http://lipidlibrary.aocs.org/lipids/lipoprot/index.htm.
20. Noga AA, Zhao Y, Vance DE: An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins. J Biol Chem 2002;277:42358-42365.
21. Pynn CJ, Henderson NG, Clark H, Koster G, Bernhard W, Postle AD: Specificity and rate of human and mouse liver and plasma phosphatidylcholine synthesis analyzed in vivo. J Lipid Res 2011;52:399-407.
22. Innis SM, Hasman D: Evidence of choline depletion and reduced betaine and dimethylglycine with increased homocysteine in plasma of children with cystic fibrosis. J Nutr 2006;136: 2226-2231.
23. Cole LK, Vance JE, Vance DE: Phosphatidylcholine biosynthesis and lipoprotein metabolism. Biochim Biophys Acta 2012;1821:754-761.
24. Bernhard W, Pynn CJ, Jaworski A, Rau GA, Hohlfeld JM, Freihorst J, Poets CF, Stoll D, Postle AD: Mass spectrometric analysis of surfactant metabolism in human volunteers using deuterated choline. Am. J. Respir. Crit. Care Med 2004;170:54-58.
25. Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-917.
26. Pynn CJ, Picardi MV, Nicholson T, Wistuba D, Poets CF, Schleicher E, Perez-Gil J, Bernhard W:. Myristate is selectively incorporated into surfactant and decreases dipalmitoylphosphatidylcholine without functional impairment. Am J Physiol Regul Integr Comp Physiol 2010;299:R1306-R1316.
27. Bernhard W, Raith M, Koch V, Kunze R, Maas C, Abele H, Poets CF, Franz AR: Plasma phospholipids indicate impaired fatty acid homeostasis in preterm infants. Eur J Nutr 2014;53:1533-1547
28. Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, Weed DA, Gelrud A, Regan MM, Laposata M, Alvarez JG, O'Sullivan BP: Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med 2004;350:560-569.
29. Leggieri E, De Biase RV, Savi D, Zullo S, Halili I, Quattrucci S: Clinical effects of diet supplementation with DHA in pediatric patients suffering from cystic fibrosis. Minerva Pediatr 2013;65:389-398.
30. Alicandro G, Faelli N, Gagliardini R, Santini B, Magazzù G, Biffi A, Risé P, Galli C, Tirelli AS, Loi S, Valmarana L, Cirilli N, Palmas T, Vieni G, Bianchi ML, Agostoni C, Colombo C: A randomized placebo-controlled study on high-dose oral algal docosahexaenoic acid supplementation in children with cystic fibrosis. Prostaglandins Leukot Essent Fatty Acids 2013;88:163-169.
31. Browning LM, Walker CG, Mander AP, West AL, Madden J, Gambell JM, Young S, Wang L, Jebb SA, Calder PC: Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish. Am J Clin Nutr 2012;96:748-758.
32. Hoving EB, van Beusekom M, Nijeboer HJ, Muskiet FAJ: Gestational age dependency of essential fatty acids in cord plasma cholesterol esters and triglycerides. Ped Res 35:461-469.
33. Uhlig, S., Gulbins, E. (2008) Sphingolipids in the lungs.Am J Respir Crit Care Med 1994;178:1100-1114.
34. Rincon M, Irvin CG: Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8:1281-1290.
35. Rehermann B, Trautwein C, Böker KH, Manns MP (1992) Interleukin-6 in liver diseases. J Hepatol 2012;15:277-280.
36. El-Kadre LJ, Tinoco AC: Interleukin-6 and obesity: the crosstalk between intestine, pancreas and liver. Curr Opin Clin Nutr Metab Care 2013;16:564-568.
37. Ji RR, Xu ZZ, Strichartz G, Serhan CN: Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 2011;34:599-609.
38. Hamai H, Keyserman F, Quittell LM, Worgall TS: Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J Lipid Res 2009;50:1101-1108.
39. Grassmé H, Riethmüller J, Gulbins E: Ceramide in cystic fibrosis. Handb Exp Pharmacol 2013;216:265-74.
40. Tafesse FG, Ternes P, Holthuis JCM: The multigenic sphingomyelin synthase family. J Biol Chem 2006;281:29421-29425.
41. Colombo C, Russo MC, Zazzeron L, Romano G: Liver Disease in Cystic Fibrosis. J Ped. Gastroent Nutr 2006;43:S49-S55.
42. Mimoun M, Coste TC, Lebacq J, Lebecque P, Wallemacq P, Leal T, Armand M: Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. J Nutr 2009;139:2358-2364.
43. Li Z, Agellon LB, Vance DE: Choline redistribution during adaptation to choline deprivation. J Biol Chem 2007;282:10283-10289.
44. da Costa KA, Corbin KD, Niculescu MD, Galanko JA, Zeisel SH. Identification of new genetic polymorphisms that alter the dietary requirement for choline and vary in their distribution across ethnic and racial groups. FASEB J. 2014;28:2970-2978.
45. da Costa KA, Sanders LM, Fischer LM, Zeisel SH. Docosahexaenoic acid in plasma phosphatidylcholine may be a potential marker for in vivo phosphatidylethanolamine N-methyltransferase activity in humans. Am J Clin Nutr. 2011;93:968-974.
46. Singh PR, Lele SS, Mukherjee MS: Gene polymorphisms and low dietary intake of micronutrients in coronary artery disease. J Nutrigenet Nutrigenomics 2011;4: 203-209.
47. DeLong CJ, Shen Y-J, Thomas MJ, Cui Z: Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway. J Biol Chem 1999;274:29683-29688.
48. Li Z, Vance DE: Phosphatidylcholine and choline homeostasis. J Lipid Res 2008;49: 1187-1194.
49. Innis SM, Davidson AG, Melynk S, James SJ: Choline-related supplements improve abnormal plasma methionine-homocysteine metabolites and glutathione status in children with cystic fibrosis. Am J Clin Nutr 2007;85:702-708.
50. Greenberg LD: Plasma cholesterol levels of monkeys maintained on various controlled and deficient diets. Am J Clin Nutr 1970;23:1101-1104.
51. Agellon LB, Walkey CJ, Vance DE, Kuipers F, Verkade HJ: The unique acyl chain specificity of biliary phosphatidylcholines in mice is independent of their biosynthetic origin in the liver. Hepatology 1999;30:725-729.